Study of NEO-201 in Solid Tumors Expansion Cohorts
A phase 1/2 trial of Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by Precision Biologics, Inc, active and no longer recruiting.
Overview
Study of NEO-201 in Solid Tumors Expansion Cohorts is a phase 1/2 interventional study registered as NCT03476681 by Precision Biologics, Inc, with 121 participants planned, started 2019-01-18 and due to reach its primary completion in 2026-06-17. Interventions recorded: NEO-201 in combination with pembrolizumab. Conditions listed: Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Cancer, Uterine Cancer. No results are recorded here; the registry entry is the source.
Setting
Phase 1/2 With Expansion Cohorts in a Study of NEO-201 in Adults With Chemo-Resistant Solid Tumors
Phase
Phase 1/2
Sponsor
Precision Biologics, Inc
Registry
Enrolled
121